Qi N. Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qi N. Cui has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Shuai-Chun Lin
Glaucoma Center of San Francisco, San Francisco, CA, USA
9 shared publications - Roland Y. Lee
Penn State Health Milton S. Hershey Medical Center, Hershey, PA
8 shared publications Toshimitsu Kasuga
Department of Ophthalmology, University of California San Francisco School of Medicine, San Francisco, CA
7 shared publicationsGuofu Huang
Department of Ophthalmology, University of California, San Francisco, California; Department of Ophthalmology, Nanchang University, Nanchang, Jiangxi Province, China
6 shared publicationsJoshua L. Dunaief
F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA
6 shared publicationsVictoria Addis
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA
6 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 35 (10) , 725-732
African Ancestry–Specific OCT Normative Database Alters Retinal Nerve Fiber Layer Classification in Primary Open Angle Glaucoma
Precis: Our study showed a lower occurrence of primary open angle glaucoma in African ancestry patients when taking their ancestry into consideration compared with the Cirrus HD-OCT classification. Purpose: Structural differences in the retinal nerve fiber layer (RNFL) of African ancestry individuals are underrepresented in the Cirrus HD-OCT normative database. Our prior study reclassified primary open angle glaucoma (POAG) color codes using RNFL data from healthy African ancestry controls. This study compares color-code classification between the Cirrus database and our reclassification for African ancestry POAG cases. Patients: A total of 787 eyes from the Primary Open Angle African American Glaucoma Genetics (POAAGG) study. Methods: Eyes were staged using the Enhanced Glaucoma Staging System (GSS2), and RNFL thickness color codes were reclassified based on an African ancestry-specific cohort. Results: The POAAGG reclassification model reported fewer abnormal yellow and red color codes (16.4% and 6.3%) than Cirrus (18.0% and 9.4%, P P P =0.04). Similar patterns were seen in quadrant-specific and stage-specific analyses. Conclusions: The discrepancy in POAG color-code classification suggests that an ancestry-conscious normative database may reduce overdiagnosis in African ancestry individuals.
- 3 July 2026
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 35 (10) , 725-732
Open AccessAfrican Ancestry–Specific OCT Normative Database Alters Retinal Nerve Fiber Layer Classification in Primary Open Angle Glaucoma
Precis: Our study showed a lower occurrence of primary open angle glaucoma in African ancestry patients when taking their ancestry into consideration compared with the Cirrus HD-OCT classification. Purpose: Structural differences in the retinal nerve fiber layer (RNFL) of African ancestry individuals are underrepresented in the Cirrus HD-OCT normative database. Our prior study reclassified primary open angle glaucoma (POAG) color codes using RNFL data from healthy African ancestry controls. This study compares color-code classification between the Cirrus database and our reclassification for African ancestry POAG cases. Patients: A total of 787 eyes from the Primary Open Angle African American Glaucoma Genetics (POAAGG) study. Methods: Eyes were staged using the Enhanced Glaucoma Staging System (GSS2), and RNFL thickness color codes were reclassified based on an African ancestry-specific cohort. Results: The POAAGG reclassification model reported fewer abnormal yellow and red color codes (16.4% and 6.3%) than Cirrus (18.0% and 9.4%, P P P =0.04). Similar patterns were seen in quadrant-specific and stage-specific analyses. Conclusions: The discrepancy in POAG color-code classification suggests that an ancestry-conscious normative database may reduce overdiagnosis in African ancestry individuals.
- Open Access
- 7 March 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 254, 110325
Loss of monocyte chemoattractant protein-1 reduced monocyte recruitment and preserved retinal ganglion cells in a mouse model of hypertensive glaucoma
- 7 March 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 254, 110325
Open AccessLoss of monocyte chemoattractant protein-1 reduced monocyte recruitment and preserved retinal ganglion cells in a mouse model of hypertensive glaucoma
- 18 November 2024
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 34 (2) , 77-83
Anticoagulation for Minimally Invasive Glaucoma Surgery: An American Glaucoma Society Survey
Precis: Perspectives and practice patterns regarding perioperative anticoagulation management and minimally invasive glaucoma surgery were queried among surgeons of American Glaucoma Society. Management varied based on surgeon preference and type of procedure performed. Purpose: The purpose of this study was to characterize anticoagulation and antiplatelet practice patterns for minimally invasive glaucoma surgery (MIGS) in the perioperative period. Materials and Methods: This was a survey of surgeons of American Glaucoma Society (AGS) about anticoagulation decision-making for their most performed MIGS procedures. Results: A total of 103 surgeons completed the survey, with 43.6% in an academic setting, 49.5% in a private practice setting, and 6.8% in a mixed practice. Median MIGS per month was 10 (IQR 20-5). The two most performed MIGS were trabecular meshwork (TM) bypass with either device implantation (24.9%) or tissue excision (40.0%). Half of respondents (50.5%) deferred to the primary care physician about anticoagulation most/all the time. Most (59.3%) managed anticoagulation differently for MIGS compared to trabeculectomy and tube implantation. Respondents reported an average of 1.3 (SD 2.5) bleeding complications related to anticoagulation and MIGS in the last year. Bleeding risk perception depended upon the type of surgery (e.g., 74.0% reported no/mild concern regarding surgeries involving TM bypass with device implantation vs. 48.0% reported high concern for TM bypass with tissue excision). Respondents stopped blood thinners at the highest rates for procedures enhancing aqueous outflow through the subconjunctival space and stopped least frequently for iStent implantation. Antiplatelets were held for a longer duration than anticoagulants prior to surgery, and most resumed both agents within 1–4 days after surgery. Conclusions: Anticoagulation management is highly varied, and this study may help to inform practice guidelines and optimize surgical outcomes by elucidating surgeon perspectives toward MIGS and anticoagulation management.
- 18 November 2024
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 34 (2) , 77-83
Anticoagulation for Minimally Invasive Glaucoma Surgery: An American Glaucoma Society Survey
Precis: Perspectives and practice patterns regarding perioperative anticoagulation management and minimally invasive glaucoma surgery were queried among surgeons of American Glaucoma Society. Management varied based on surgeon preference and type of procedure performed. Purpose: The purpose of this study was to characterize anticoagulation and antiplatelet practice patterns for minimally invasive glaucoma surgery (MIGS) in the perioperative period. Materials and Methods: This was a survey of surgeons of American Glaucoma Society (AGS) about anticoagulation decision-making for their most performed MIGS procedures. Results: A total of 103 surgeons completed the survey, with 43.6% in an academic setting, 49.5% in a private practice setting, and 6.8% in a mixed practice. Median MIGS per month was 10 (IQR 20-5). The two most performed MIGS were trabecular meshwork (TM) bypass with either device implantation (24.9%) or tissue excision (40.0%). Half of respondents (50.5%) deferred to the primary care physician about anticoagulation most/all the time. Most (59.3%) managed anticoagulation differently for MIGS compared to trabeculectomy and tube implantation. Respondents reported an average of 1.3 (SD 2.5) bleeding complications related to anticoagulation and MIGS in the last year. Bleeding risk perception depended upon the type of surgery (e.g., 74.0% reported no/mild concern regarding surgeries involving TM bypass with device implantation vs. 48.0% reported high concern for TM bypass with tissue excision). Respondents stopped blood thinners at the highest rates for procedures enhancing aqueous outflow through the subconjunctival space and stopped least frequently for iStent implantation. Antiplatelets were held for a longer duration than anticoagulants prior to surgery, and most resumed both agents within 1–4 days after surgery. Conclusions: Anticoagulation management is highly varied, and this study may help to inform practice guidelines and optimize surgical outcomes by elucidating surgeon perspectives toward MIGS and anticoagulation management.
- 1 November 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 270, 275-276
Response to: “Comment on: Association between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change”
- 1 November 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 270, 275-276
Response to: “Comment on: Association between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change”
- 3 September 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 269, 255-265
Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change
- 3 September 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 269, 255-265
Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change
- Open Access
Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change
Objective This study aims to provide data on the effects of glucagon-like peptide 1 receptor (GLP-1R) agonists on intraocular pressure (IOP). Design Retrospective cohort study. Subjects, Participants, and/or Controls 1247 glaucoma surgery and treatment naïve eyes of 626 patients who were initiated on GLP-1R agonists compared to 1083 glaucoma surgery and treatment naïve eyes of 547 patients who were initiated on other oral antidiabetics. Methods, Intervention, or Testing The University of California Health Data Warehouse was queried for patients exposed to GLP-1R agonists or other oral antidiabetics. Index date was defined as the date of first exposure to the medication. Eyes with at least one pre-exposure and one post-exposure tonometry record within 365 days of the index date were included in the analysis. Clinical and laboratory data elements were extracted from the database. Eyes were censored from the analysis upon exposure to glaucoma hypotensive medication or glaucoma surgery. ΔIOP was analyzed using a paired t-test. Regression analysis was conducted using generalized estimating equations (GEE) accounting for inter-eye correlation. Sensitivity analyses were performed to assess the robustness of the findings. Main Outcome Measures Primary outcome measure was ΔIOP after exposure to the medication. Results The median age of all included subjects was 66.2 years [IQR=18.3]; 607 (51.7%) were female, and 667 (56.9%) were Caucasian. Median pre-exposure IOP, HbA1c, and BMI were 15.2 mmHg [IQR=3.8], 7.5 [IQR=2.4], and 29.8 [IQR=9.4], respectively. 776 individuals (66.1%) had diabetes, with the median number of active oral antidiabetics being 1.0 [IQR=1.0], and 441 (37.5%) being insulin users. Several pre-exposure characteristics significantly differed between the GLP-1R agonist and the control group. The mean ΔIOP was -0.4±2.8 mmHg (paired t-test pConclusions Although GLP-1R agonists were significantly associated with a decrease in IOP in the paired analysis, they were not associated with ΔIOP in multivariable GEE. Moreover, the difference between the ΔIOP in the two groups was small. Future prospective studies following a standardized dose and delivery method may provide further insights.
Open AccessAssociation between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change
Objective This study aims to provide data on the effects of glucagon-like peptide 1 receptor (GLP-1R) agonists on intraocular pressure (IOP). Design Retrospective cohort study. Subjects, Participants, and/or Controls 1247 glaucoma surgery and treatment naïve eyes of 626 patients who were initiated on GLP-1R agonists compared to 1083 glaucoma surgery and treatment naïve eyes of 547 patients who were initiated on other oral antidiabetics. Methods, Intervention, or Testing The University of California Health Data Warehouse was queried for patients exposed to GLP-1R agonists or other oral antidiabetics. Index date was defined as the date of first exposure to the medication. Eyes with at least one pre-exposure and one post-exposure tonometry record within 365 days of the index date were included in the analysis. Clinical and laboratory data elements were extracted from the database. Eyes were censored from the analysis upon exposure to glaucoma hypotensive medication or glaucoma surgery. ΔIOP was analyzed using a paired t-test. Regression analysis was conducted using generalized estimating equations (GEE) accounting for inter-eye correlation. Sensitivity analyses were performed to assess the robustness of the findings. Main Outcome Measures Primary outcome measure was ΔIOP after exposure to the medication. Results The median age of all included subjects was 66.2 years [IQR=18.3]; 607 (51.7%) were female, and 667 (56.9%) were Caucasian. Median pre-exposure IOP, HbA1c, and BMI were 15.2 mmHg [IQR=3.8], 7.5 [IQR=2.4], and 29.8 [IQR=9.4], respectively. 776 individuals (66.1%) had diabetes, with the median number of active oral antidiabetics being 1.0 [IQR=1.0], and 441 (37.5%) being insulin users. Several pre-exposure characteristics significantly differed between the GLP-1R agonist and the control group. The mean ΔIOP was -0.4±2.8 mmHg (paired t-test pConclusions Although GLP-1R agonists were significantly associated with a decrease in IOP in the paired analysis, they were not associated with ΔIOP in multivariable GEE. Moreover, the difference between the ΔIOP in the two groups was small. Future prospective studies following a standardized dose and delivery method may provide further insights.
- Open Access
- 9 August 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (5) , 2381-2395
New Devices in Glaucoma
Glaucoma remains a leading cause of blindness globally. Minimally invasive treatment techniques are rapidly expanding the availability of therapeutic options for glaucoma. These include devices aimed at enhancing outflow through the subconjunctival space, Schlemm’s canal, and suprachoroidal space, sustained-release drug delivery devices, and extraocular devices aiming to reduce glaucomatous progression through other novel means. In this review, we provide an overview of several novel devices either newly available or in development for the medical and surgical management of glaucoma. Further studies are required to determine the long-term efficacy of these devices and how they will integrate into the current landscape of glaucoma management.
- 9 August 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (5) , 2381-2395
Open AccessNew Devices in Glaucoma
Glaucoma remains a leading cause of blindness globally. Minimally invasive treatment techniques are rapidly expanding the availability of therapeutic options for glaucoma. These include devices aimed at enhancing outflow through the subconjunctival space, Schlemm’s canal, and suprachoroidal space, sustained-release drug delivery devices, and extraocular devices aiming to reduce glaucomatous progression through other novel means. In this review, we provide an overview of several novel devices either newly available or in development for the medical and surgical management of glaucoma. Further studies are required to determine the long-term efficacy of these devices and how they will integrate into the current landscape of glaucoma management.
- Open Access
- 9 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17, 1156829
Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
Glaucomatous neurodegeneration, a blinding disease affecting millions worldwide, has a need for the exploration of new and effective therapies. Previously, the glucagon-like peptide-1 receptor (GLP-1R) agonist NLY01 was shown to reduce microglia/macrophage activation, rescuing retinal ganglion cells after IOP elevation in an animal model of glaucoma. GLP-1R agonist use is also associated with a reduced risk for glaucoma in patients with diabetes. In this study, we demonstrate that several commercially available GLP-1R agonists, administered either systemically or topically, hold protective potential in a mouse model of hypertensive glaucoma. Further, the resulting neuroprotection likely occurs through the same pathways previously shown for NLY01. This work contributes to a growing body of evidence suggesting that GLP-1R agonists represent a viable therapeutic option for glaucoma.
- 9 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17, 1156829
Open AccessTopical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
Glaucomatous neurodegeneration, a blinding disease affecting millions worldwide, has a need for the exploration of new and effective therapies. Previously, the glucagon-like peptide-1 receptor (GLP-1R) agonist NLY01 was shown to reduce microglia/macrophage activation, rescuing retinal ganglion cells after IOP elevation in an animal model of glaucoma. GLP-1R agonist use is also associated with a reduced risk for glaucoma in patients with diabetes. In this study, we demonstrate that several commercially available GLP-1R agonists, administered either systemically or topically, hold protective potential in a mouse model of hypertensive glaucoma. Further, the resulting neuroprotection likely occurs through the same pathways previously shown for NLY01. This work contributes to a growing body of evidence suggesting that GLP-1R agonists represent a viable therapeutic option for glaucoma.
- Open Access
- 2 March 2023
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 8 (1) , e001120
Risk factors for structural and functional progression of primary open-angle glaucoma in an African ancestry cohort
Background/aims To investigate the rates of structural and functional progression of primary open-angle glaucoma in an African ancestry cohort and identify risk factors for progression. Methods This retrospective study included 1424 eyes from glaucoma cases in the Primary Open-Angle African American Glaucoma Genetics cohort, with ≥2 visits for retinal nerve fibre layer (RNFL) thickness and mean deviation (MD) measurements over ≥6-month follow-up. The rates of structural progression (change in RNFL thickness/year) and functional progression (change in MD/year) were calculated from linear mixed effects models, accounting for intereye correlation and longitudinal correlation. Eyes were categorised as slow, moderate or fast progressors. Risk factors for progression rates were assessed using univariable and multivariable regression models. Results The median (interquartile) rates of progression were −1.60 (−2.05 to –1.15) µm/year for RNFL thickness and −0.40 (−0.44 to –0.34) decibels/year for MD. Eyes were categorised as slow (structural: 19%, functional: 88%), moderate (structural: 54%, functional: 11%) and fast (structural: 27%, functional: 1%) progressors. In multivariable analysis, faster RNFL progression was independently associated with thicker baseline RNFL (pConclusion The median rates of structural and functional progression in this African ancestry cohort were faster than the rates reported from previously published studies in other ethnic groups. Higher baseline RNFL thickness and MD values were associated with faster progression rates. Results highlight the importance of monitoring structural and functional glaucoma progression to provide timely treatment in early disease.
- 2 March 2023
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 8 (1) , e001120
Open AccessRisk factors for structural and functional progression of primary open-angle glaucoma in an African ancestry cohort
Background/aims To investigate the rates of structural and functional progression of primary open-angle glaucoma in an African ancestry cohort and identify risk factors for progression. Methods This retrospective study included 1424 eyes from glaucoma cases in the Primary Open-Angle African American Glaucoma Genetics cohort, with ≥2 visits for retinal nerve fibre layer (RNFL) thickness and mean deviation (MD) measurements over ≥6-month follow-up. The rates of structural progression (change in RNFL thickness/year) and functional progression (change in MD/year) were calculated from linear mixed effects models, accounting for intereye correlation and longitudinal correlation. Eyes were categorised as slow, moderate or fast progressors. Risk factors for progression rates were assessed using univariable and multivariable regression models. Results The median (interquartile) rates of progression were −1.60 (−2.05 to –1.15) µm/year for RNFL thickness and −0.40 (−0.44 to –0.34) decibels/year for MD. Eyes were categorised as slow (structural: 19%, functional: 88%), moderate (structural: 54%, functional: 11%) and fast (structural: 27%, functional: 1%) progressors. In multivariable analysis, faster RNFL progression was independently associated with thicker baseline RNFL (pConclusion The median rates of structural and functional progression in this African ancestry cohort were faster than the rates reported from previously published studies in other ethnic groups. Higher baseline RNFL thickness and MD values were associated with faster progression rates. Results highlight the importance of monitoring structural and functional glaucoma progression to provide timely treatment in early disease.
- Open Access
- 23 December 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 29, 101786
Elevated IOP following a bladder filling protocol: A case report
- 23 December 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 29, 101786
Open AccessElevated IOP following a bladder filling protocol: A case report